Lipophilic arabinofuranosyl cytosine derivatives in liposomes

Methods in Enzymology

Volumn 391, Issue SPEC. ISS., 2005, Pages 58-70

  Schwendener, Reto ^a   Schott, Herbert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 2'DEOXYURIDYLYL (5'-5') N 4 OCTADECYL 1 BETA DEXTRO ARABINOCYTIDINE; ALPHA TOCOPHEROL; ARABINOCYTIDYLYL (5'-5') N 4 OCTADECYL 1 BETA DEXTRO ARABINOCYTIDINE; CHOLESTEROL; CISPLATIN; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; CYTARABINE DERIVATIVE; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; LIPOSOME; MACROGOL; MITOMYCIN C; N 4 OCTADECYL 1 BETA DEXTRO ARABINOFURANOSYLCYTOSINE; NUCLEOSIDE DERIVATIVE; PHOSPHATIDYLCHOLINE; PLASMA PROTEIN; SOY PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG; VINCRISTINE; WATER; ZALCITABINE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CELL; CANCER INHIBITION; CELL ASSAY; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CYTOTOXICITY; DEAMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TOLERABILITY; HEMATOPOIETIC STEM CELL; HUMAN; IN VIVO STUDY; LIPID BILAYER; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; SOLUBILITY; STATISTICAL SIGNIFICANCE; TOXICITY TESTING;

ARA; MURINAE;

EID: 13844256146     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)91003-3     Document Type: Article

References (29)

1. Allen T.M., Hansen C., Martin F., Redemann C., Yau Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:1991;29-36
2. Cattaneo-Pangrazzi R.M.C., Schott H., Wunderli-Allenspach H., Derighetti M.I., Schwendener R.A. New amphiphilic heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine (5FdUrd): Cell cycle dependent cytotoxicity and induction of apoptosis in PC-3 prostate tumor cells. Biochem. Pharmacol. 60:2000a;1887-1896
3. Cattaneo-Pangrazzi R.M.C., Schott H., Schwendener R.A. The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. The Prostate. 45:2000b;8-18
4. Gabizon A., Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 54:(Suppl. 4):1997;15-21
5. Hong C.I., West C.R., Bernacki R.J., Tebbi C.K., Berdel W.E. 1-β-D-arabinofuranosylcytosine conjugates of ether and thioether phospholipids. A new class of ara-C prodrugs with improved antitumor activity. Lipids. 26:1991;1437-1444
6. 4-hexadecyl-1- β-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J. Pharm. Pharmacol. 47:1995a;282-288
7. 4-hexadecyl-1-β-D- arabinofuranosylcytosine, a lipophilic derivative of 1-β-D- arabinofuranosylcytosine. Br. J. Cancer. 71:1995b;957-962
8. 4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) in the human leukemic cell lines K-562 and U-937. Cancer Chemother. Pharmacol. 36:1995c;483-492
9. 4-octadecyl-1-β-D-ara-C. J. Cancer Res. Clin. Oncol. 126:2000;311-319
10. 4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC), a new anticancer drug. J. Pharmacol. Exp. Ther. 282:1997;1572-1580
11. 4-octadecyl-1- β-D-arabinofuranosylcytosine (NOAC) in mice. Drug Metab. Disposition. 27:1999a;342-350
12. 4-octadecyl-1- β-D-arabinofuranosylcytosine (NOAC) in Daudi lymphoma cells. Br. J. Cancer. 80:1999b;1542-1549
13. Matsushita T., Ryu E.K., Hong C.I., MacCoss M. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability. Cancer Res. 41:1981;2707-2713
14. Pestalozzi, B., Schwendener, R.A. (1999). Unpublished data.
15. 4-octadecyl-1-β-D- arabinofuranosylcytosine in plasma and erythrocytes. J. Chromatogr. B. 673:1995;259-266
16. 4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC) in plasma and whole blood after intravenous and oral application in mice. J. Pharm. Pharmacol. 49:1997;1076-1081
17. Rubas W., Supersaxo A., Weder H.G., Hartmann H.R., Hengartner H., Schott H., Schwendener R.A. Treatment of murine L1210 leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int. J. Cancer. 37:1986;149-154
18. 4-hexadecyl-1-β-D-arabinofuranosylcytosin, zwei Vertreter einer neuen Prodrug-Gruppe. Liebigs Annalen der Chemie. 1994;277-282
19. Schott H., Schwendener R.A., Guerin A. Amphiphilic nucleosidephosphate analogues. 1997;. U.S. Patent 5,679,652.
20. Schwendener R.A. The preparation of large volumes of sterile liposomes for clinical applications. Gregoriadis G. "Liposome Technology" 2nd ed.:1993;487-500 CRC Press, Boca Raton, FL
21. 4-hexadecyl-1-β-D- arabinofuranosylcytosine. Int. J. Cancer. 51:1992;466-469
22. Schwendener R.A., Schott H. Lipophilic 1-β-D- arabinofuranosylcytosine derivatives in liposomal formulations for oral and parenteral antitleukemic therapy in the murine L1210 leukemia model. J. Cancer Res. Clin. Oncol. 122:1996;723-726
23. Schwendener R.A., Asanger M., Weder H.G. The preparation of large bilayer liposomes: controlled removal of n-alkyl-glucoside detergents from lipid/detergent micelles. Biochem. Biophys. Res. Commun. 100:1981;1055-1062
24. Schwendener R.A., Horber D.H., Gowland P., Zahner R., Schertler A., Schott H. New lipophilic acyl/alkyl dinucleoside phosphates as derivatives of 3′-azido-3′-deoxythymidine: Inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Antiviral Res. 24:1994;79-93
25. 4-octadecyl-ara-C, NOAC. Drugs Future. 20:1995a;11-15
26. 4-octadecyl-1-β-D- arabinofuranosylcytosine in liposomal preparations. J. Liposome Res. 5:1995b;27-47
27. 4alkyl derivatives of 1-β-D-arabinofuranosylcytosine (arc-C). J. Cancer Res. Clin. Oncol. 122:1996;102-108
28. 4-octadecyl-1-β-D- arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-β-D-arabinofuranocylcytosine on biopsized clonogenic human tumour cells and haematopoietic precursor cells. Invest. New Drugs. 19:2001;203-210
29. Ueda T., Kamiya K., Urasaki Y., Wataya S., Kawai Y., Tsutani H., Sugiyama M., Nakamura T. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine- 5′-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res. 54:1994;109-113